Login to Your Account

Swiss Start-up Piqur Develops Dual PI3K-mTOR Inhibitors

By Cormac Sheridan
Staff Writer

Tuesday, February 12, 2013
Matthias Wymann, the Swiss scientist who discovered the first phosphoinositide 3-kinase (PI3K) inhibitor, is co-founder of a new cancer drug discovery start-up, Piqur Therapeutics AG, which recently completed a seed financing round that will enable it take forward a pipeline of next-generation kinase inhibitors.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription